Active Ingredient History
BGB-3111 is a potent and highly selective small molecule BTK inhibitor (Bruton’s Tyrosine Kinase), which we are developing as a monotherapy and in combination with other therapies for the treatment of a variety of lymphomas—the most common form of blood cancer. BGB-3111 blocks the signaling that leads to growth inhibition and cell death in malignant B-cells. In preclinical studies, BGB-3111 showed more restricted off-target activities against a panel of kinases, including ITK. Due to the weaker activity on ITK, BGB-3111 was at least 10 times weaker than ibrutinib in inhibiting rituximab-induced ADCC activity. Both in the REC-1 MCL and ABC subtype DLBCL (TMD-8) xenograft models, BGB-3111 induced dose-dependent antitumor effects and demonstrated superior efficacy in comparison with ibrutinib. Toxicity study in rats indicated that BGB-3111 was very well tolerated, and the MTD was not reached when it was dosed up to 250 mg/ kg/day. The first-in-human, open-label phase 1 trial of BGB-3111 is ongoing as a modified 3 + 3 dose-escalation design (40, 80, 160, 320 mg PO QD; 160 mg PO BID) in patients with advanced B cell malignancies. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Leukemia, Lymphocytic, Chronic, B-Cell (approved 2023)
Lymphoma, Mantle-Cell (approved 2019)
Waldenstrom Macroglobulinemia (approved 2022)
Agammaglobulinaemia Tyrosine Kinase (Phase 1/Phase 2)
Anemia, Hemolytic, Autoimmune (Phase 2)
Anemia, Refractory (Phase 2)
Antiphospholipid Syndrome (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Castleman Disease (Phase 2)
COVID-19 (Phase 2)
Healthy Volunteers (Phase 1)
Hodgkin Disease (Phase 3)
Immunoglobulin G4-Related Disease (Phase 2)
Kidney Diseases (Phase 2/Phase 3)
Leukemia (Phase 1)
Leukemia, B-Cell (Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Lymphoid (Phase 2)
Leukemia, Myeloid, Acute (Phase 1/Phase 2)
Lupus Nephritis (Phase 2)
Lymphohistiocytosis, Hemophagocytic (Phase 3)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 3)
Lymphoma, Follicular (Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 3)
Lymphoma, T-Cell (Phase 2)
Male (Phase 1)
Melanoma (Phase 1/Phase 2)
Mutation (Phase 2)
Myelodysplastic Syndromes (Phase 1/Phase 2)
Neoplasms (Phase 2)
Neuromyelitis Optica (Phase 2)
Purpura, Thrombocytopenic, Idiopathic (Phase 2)
Therapeutics (Phase 2)
Thrombocytopenia (Phase 2)
Waldenstrom Macroglobulinemia (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue